| P50 | author | Jan Stenvang | Q42640387 |
| | José Moreira | Q60624375 |
| P2093 | author name string | Nils Brünner | |
| | David Hersi Smith | |
| | Dorte Nielsen | |
| | Iben Kümler | |
| | Sune Boris Nygård | |
| P2860 | cites work | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 |
| | MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 |
| | Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy | Q27851526 |
| | Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 |
| | Repair of and checkpoint response to topoisomerase I-mediated DNA damage | Q28187875 |
| | Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer | Q28287018 |
| | The landscape of somatic copy-number alteration across human cancers | Q29547648 |
| | Topoisomerase I inhibitors: camptothecins and beyond | Q29614976 |
| | RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 |
| | Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration | Q30514241 |
| | Integration of DNA copy number alterations and transcriptional expression analysis in human gastric cancer. | Q31059013 |
| | Molecular determinants of irinotecan efficacy. | Q33253178 |
| | Effective incorporation of biomarkers into phase II trials | Q33870594 |
| | Finding promiscuous old drugs for new uses | Q33910025 |
| | A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors | Q33924277 |
| | HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data | Q34019589 |
| | Randomized clinical trials with biomarkers: design issues | Q34024227 |
| | Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34121226 |
| | Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial | Q34581085 |
| | Processing of topoisomerase I cleavable complexes into DNA damage by transcription. | Q34642113 |
| | Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Q34653756 |
| | Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort | Q34663849 |
| | Use of archived specimens in evaluation of prognostic and predictive biomarkers | Q35007222 |
| | Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership | Q35927074 |
| | Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819 | Q36133455 |
| | DNA damage-induced cell death by apoptosis. | Q36561337 |
| | Second act: Drug repurposing gets a boost as academic researchers join the search for novel uses of existing drugs | Q36616974 |
| | CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues | Q36617921 |
| | Economics of new oncology drug development | Q36702518 |
| | Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers | Q36955892 |
| | Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy | Q37207935 |
| | Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas | Q37229378 |
| | Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. | Q37252144 |
| | Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. | Q37325013 |
| | The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities | Q37987661 |
| | Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines | Q38081660 |
| | A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer | Q38091335 |
| | Guidelines and considerations for conducting experiments using tissue microarrays | Q38106730 |
| | Polypharmacology - foe or friend? | Q38126927 |
| | Cancer drug discovery by repurposing: teaching new tricks to old dogs | Q38127534 |
| | HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients | Q38418568 |
| | TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity | Q39428021 |
| | Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis | Q39528312 |
| | Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. | Q39608822 |
| | Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis. | Q39704361 |
| | Randomized phase III clinical trial designs for targeted agents | Q42165255 |
| | Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer | Q42165463 |
| | Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study | Q42621663 |
| | Elevations of DNA topoisomerase I in invasive carcinoma of the breast | Q43685655 |
| | Human DNA topoisomerase I: An anticancer drug target present in human sarcomas | Q44085652 |
| | Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan | Q44097380 |
| | Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival | Q44604732 |
| | Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. | Q44916903 |
| | Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas | Q44929867 |
| | Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients | Q44937059 |
| | Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. | Q46006799 |
| | Quo vadis with targeted drugs in the 21st century? | Q46220360 |
| | Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial | Q46570394 |
| | retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: | Q46761542 |
| | Ovarian cancer, version 3.2012. | Q47562494 |
| | Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q48293335 |
| | Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. | Q53232788 |
| | Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. | Q54189857 |
| | P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy | Q54286228 |
| | When to order a biopsy to characterise a metastatic relapse in breast cancer. | Q54481754 |
| | Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. | Q54513618 |
| | Objective assessment of cancer genes for drug discovery | Q57001160 |
| | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making | Q57758061 |
| | Molecular prescreening to select patient population in early clinical trials | Q58614572 |
| | Small cell lung cancer | Q60021974 |
| | DNA-topoisomerase I activity and content in epithelial ovarian cancer | Q60192922 |
| | Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy | Q61443507 |
| | DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts | Q69360455 |
| | Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies | Q71249676 |
| | Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes | Q72092461 |
| | Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy | Q72692099 |
| | CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants | Q73074284 |
| | Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer | Q73803404 |
| | Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas | Q73936657 |
| | Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas | Q73984099 |
| | Proficient metabolism of irinotecan by a human intestinal carboxylesterase | Q74314817 |
| | Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression | Q77340375 |
| | Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon | Q77403763 |
| | Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma | Q77585426 |
| | Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases | Q78582048 |
| | Sensitivity to CPT-11 and platinum derivatives of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses | Q80051457 |
| | Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy | Q80554169 |
| | Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803 | Q80768425 |
| | Resisting targeted therapy: fifty ways to leave your EGFR | Q83827641 |
| | Drug repurposing programmes get lift off | Q84489618 |
| | Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q85009910 |
| | Systemic treatment of advanced pancreatic cancer--step by step progress | Q95407890 |
| P921 | main subject | biomarker | Q864574 |
| | chemotherapy | Q974135 |
| P304 | page(s) | 313 | |
| P577 | publication date | 2013-12-25 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development | |
| P478 | volume | 3 | |